Literature DB >> 3141702

X-linked adrenoleukodystrophy: identification of the primary defect at the level of a deficient peroxisomal very long chain fatty acyl-CoA synthetase using a newly developed method for the isolation of peroxisomes from skin fibroblasts.

R J Wanders1, C W van Roermund, M J van Wijland, R B Schutgens, A W Schram, J M Tager, H van den Bosch, C Schalkwijk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3141702     DOI： 10.1007/bf01804228

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  9 in total

1.  Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex.

Authors:  I Singh; H W Moser; A B Moser; Y Kishimoto
Journal:  Biochem Biophys Res Commun       Date:  1981-10-30       Impact factor: 3.575

2.  Adrenoleukodystrophy: very long-chain fatty acid metabolism in fibroblasts.

Authors:  W B Rizzo; J Avigan; J Chemke; J D Schulman
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

3.  Peroxisomal fatty acid beta-oxidation in relation to the accumulation of very long chain fatty acids in cultured skin fibroblasts from patients with Zellweger syndrome and other peroxisomal disorders.

Authors:  R J Wanders; C W van Roermund; M J van Wijland; R B Schutgens; J Heikoop; H van den Bosch; A W Schram; J M Tager
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

4.  X-linked adrenoleukodystrophy: defective peroxisomal oxidation of very long chain fatty acids but not of very long chain fatty acyl-CoA esters.

Authors:  R J Wanders; C W van Roermund; M J van Wijland; A A Nijenhuis; A Tromp; R B Schutgens; E M Brouwer-Kelder; A W Schram; J M Tager; H van den Bosch
Journal:  Clin Chim Acta       Date:  1987-06-15       Impact factor: 3.786

5.  Metabolism of [17,18-3H2]hexacosanoic acid and [15,16-3H2]lignoceric acid in cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN).

Authors:  S Tsuji; T Sano-Kawamura; T Ariga; T Miyatake
Journal:  J Neurol Sci       Date:  1985-12       Impact factor: 3.181

6.  Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy.

Authors:  I Singh; A E Moser; S Goldfischer; H W Moser
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

7.  Lignoceroyl-CoASH ligase: enzyme defect in fatty acid beta-oxidation system in X-linked childhood adrenoleukodystrophy.

Authors:  M Hashmi; W Stanley; I Singh
Journal:  FEBS Lett       Date:  1986-02-17       Impact factor: 4.124

8.  Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.

Authors:  H W Moser; A E Moser; I Singh; B P O'Neill
Journal:  Ann Neurol       Date:  1984-12       Impact factor: 10.422

9.  Studies on the peroxisomal oxidation of palmitate and lignocerate in rat liver.

Authors:  R J Wanders; C W van Roermund; M J van Wijland; R B Schutgens; A W Schram; H van den Bosch; J M Tager
Journal:  Biochim Biophys Acta       Date:  1987-05-13
  9 in total
  10 in total

Review 1.  Peroxisomal acyl-CoA synthetases.

Authors:  Paul A Watkins; Jessica M Ellis
Journal:  Biochim Biophys Acta       Date:  2012-02-17

2.  X-linked adrenoleukodystrophy and haemophilia A in the same kindred.

Authors:  A Nogueira; P Jorge; J Dores; M Cunha; S Sousa; I Pereira; M Campos; B Justiça; D Quelhas; M Sá Miranda
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

3.  Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts.

Authors:  N Cartier; J Lopez; P Moullier; F Rocchiccioli; M O Rolland; P Jorge; J Mosser; J L Mandel; P F Bougnères; O Danos
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

4.  Mutations in the gene for X-linked adrenoleukodystrophy in patients with different clinical phenotypes.

Authors:  A Braun; H Ambach; S Kammerer; B Rolinski; S Stöckler; W Rabl; J Gärtner; S Zierz; A A Roscher
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

5.  Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters.

Authors:  G C Korenke; D H Hunneman; J Kohler; S Stöckler; K Landmark; F Hanefeld
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

6.  A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern.

Authors:  G Lombard-Platet; S Savary; C O Sarde; J L Mandel; G Chimini
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

7.  The red-green visual pigment gene region in adrenoleukodystrophy.

Authors:  P Aubourg; R Feil; S Guidoux; J C Kaplan; H Moser; A Kahn; J L Mandel
Journal:  Am J Hum Genet       Date:  1990-03       Impact factor: 11.025

8.  Neurodegeneration in a Drosophila model of adrenoleukodystrophy: the roles of the Bubblegum and Double bubble acyl-CoA synthetases.

Authors:  Anna Sivachenko; Hannah B Gordon; Suzanne S Kimball; Erin J Gavin; Joshua L Bonkowsky; Anthea Letsou
Journal:  Dis Model Mech       Date:  2016-02-18       Impact factor: 5.758

9.  Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy.

Authors:  Nathalie Launay; Montserrat Ruiz; Laia Grau; Francisco J Ortega; Ekaterina V Ilieva; Juan José Martínez; Elena Galea; Isidre Ferrer; Erwin Knecht; Aurora Pujol; Stéphane Fourcade
Journal:  Acta Neuropathol       Date:  2016-12-21       Impact factor: 17.088

10.  Impaired very long-chain acyl-CoA β-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction.

Authors:  Christoph Wiesinger; Markus Kunze; Günther Regelsberger; Sonja Forss-Petter; Johannes Berger
Journal:  J Biol Chem       Date:  2013-05-13       Impact factor: 5.157
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.